Research programme: eye disorder protein therapeutics - Sesen Bio

Drug Profile

Research programme: eye disorder protein therapeutics - Sesen Bio

Alternative Names: EBI-006; EBI-018; EBI-028; EBI-029; EBI-031

Latest Information Update: 18 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eleven Biotherapeutics
  • Developer Sesen Bio
  • Class Proteins
  • Mechanism of Action Interleukin 1 receptor antagonists; Interleukin 17 receptor antagonists; Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic macular oedema; Uveitis
  • Research Age-related macular degeneration; Ocular inflammation

Most Recent Events

  • 16 May 2018 Eleven Biotherapeutics is now called Sesen Bio
  • 13 Sep 2016 Eleven Biotherapeutics withdraws a phase I trial prior to enrolment for Diabetic macular oedema in USA (NCT02842541)
  • 07 Jul 2016 US FDA approves IND application for EBI 031 in Diabetic macular oedema and uveitis (9201624; 9199120)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top